Skip to main content
Metallomix

Investor Corner:  Frequently Asked Questions & Answers

Save time and find answers to frequently asked questions about us and our business. Note that we offer investments under Rule 506(c) only to accredited investors.

Company
Business
Risk Factors
Offerings
More Information
Company

Q: What is Metallomix? 

A: Metallomix Inc. conceives, acquires, and incubates pharmaceutical innovations focused on the roles that atoms of zinc, iron, magnesium, and other metals play in cellular functions throughout the body. Through its subsidiaries, the company advances a vast pipeline of proprietary isotopically modified compounds via three principal verticals: monotherapies, combination therapies, and drug analogs. Drug candidates include isotope-selective modulators of the primary metabolic, signal transduction, and gene regulation pathways with downstream therapeutic effects through GLS, NF-kB, PARP1, TNF-α, p53, and other pathways. Therapeutic benefits span over oncology, neurology, hepatology, endocrinology, hematology, cardiology, and virology areas. The company has its first lead candidate, small molecule, KLS-1, in the clinical phase and seven new molecules in preclinical development. The  is headquartered in Miami, Florida, and operates internationally.

Business

Q: What is the Metallomix' chief ultimate business goal? 

A:  Our goal is to become The #1 company in isotopic metallomics focused on developing inherently safe, effective, and clinically derisked, disease modifying therapies for treatment of complex diseases.

Risk Factors
Offerings
More Information

Q: Where can potential investors find more information? 

A: We have agreed to make available to each prospective investor the opportunity to ask questions and to receive answers from our officers concerning the terms and conditions of investing into our business, and to obtain any additional information, to the extent we possess such information or can acquire it without unreasonable effort or expense. You may mail or email your questions, inquiries, and requests to: 

Metallomix, Inc.
Attn: Investor Relations

175 SW 7-th Street, Unit 1702, Miami, Florida 33130

                                 eMail: IR@Metallomix.com
Q: WHAT IS METALLOME?

A: The metallome – metals in human biology and disease – plays an integral role in various biological functions, including amino acid and protein synthesis, DNA integrity and repair, and mitochondrial metabolism.  We are leading the way in illuminating a metallome much more nuanced than simply the function of specific metals or oxidation states, offering a massive and previously unexplored opportunity for drug discovery and development. 

Q: HOW DOES METALLOMIX CREATE STOCKHOLDER VALUE?

A: We pursue the creation of shareholder value through the corporate strategy that involves developing products within a subsidiary structure, incubating them under the parent company’s resources, and ultimately spinning them off into publicly traded entities. We believe this strategy will allow Metallomix to gradually unlock not only 64Zn-based, but the entire metallome value, streamline operations, and capitalize on specialized market opportunities. This approach will enable the company to balance innovation with shareholder value creation by combining the agility of focused subsidiary development with the financial and operational benefits of spin-offs. The exponential progress may be achieved by leveraging KLS-1 expansion (upon approval of our NDA by the FDA) as mono- and combination therapies throuout additional therapeutic indications using the regulatory pathway under Section 505(b)(2) of the FD&C Act, catalyzed by the continuous development of new 64Zn-based compounds, new isotope-selective modulators beyond 64Zn, and isotopically modifying the approved, proven drugs.

Q: WHO STARTED METALLOMIX AND WHEN?

Our founder and President Dr. Max Temnik, Ph.D., was responsible for identifying, developing and testing the initial hypothesis supporting KLS-1 drug development as a mono- and combination therapies. Prior to our formation, Dr. Temnik has started developing KLS-1 under the umbrella of Vector Vitale LLC, which is our parent licensor. In 2024, Vector Vitale has started transferring all 64Zn-related research and intellectual properties to ZnA Bio LLC, a Metallomix Company, which will carry forward the development and commercialization of KLS-1 and other zinc-based ISM products. The transition is expected to be completed by the end of 2025.

Q: WHAT IS METALLOMIX'S MISSION?

A: Our mission is to bring forward new, life-changing medicines through understanding the isotopic dysfractionation and developing safe, effective, and clinically derisked small molecular isotopic modulators.